News

AgroSpheres Secures $37M Series B Funding – Pushes for Growth

AgroSpheres Inc. (AGS), a biotechnology leader in sustainable crop protection and crop health, today announced the final close of a $37 million Series B funding round led by Zebra Impact Ventures, which invests through the Regenerative Growth I strategy, run in partnership with Mirabaud Asset Management. The round also saw strong participation from existing investors Lewis and Clark AgriFood, Ospraie Ag Science Ventures, FMC Ventures, BIDRA Ventures and Cavallo Ventures, underscoring continued confidence in the company’s trajectory in establishing itself as a premier crop health company.

This new capital will support AgroSpheres’ end-to-end product development, investment in just-in-time biomanufacturing facilities, expansion into new markets and drive further development of its revolutionary AgriCell platform, designed to enhance field performance and meet the rising global demand for sustainable agricultural solutions.

“We are thrilled to have Zebra Impact Ventures lead this funding round and grateful for the continued support of our existing investors,” said Payam Pourtaheri, Co-Founder and CEO of AgroSpheres. “Impact is at our core and Zebra’s perspective will be critical in realizing our vision of a ’future built by nature’s technologies.’ This investment will allow us to scale our operations, advance our R&D capabilities and bring our breakthrough technology to farmers around the world. Our mission is to redefine the future of agriculture with products that offer powerful performance and environmental sustainability.”

AgroSpheres’ patented AgriCell technology is a highly scalable and cost-effective platform for the manufacturing of encapsulated biomolecules. Key agronomic features of AgriCell technology include:

  1. Stabilized biomolecules that deliver superior field performance across a broad range of environmental conditions.
  2. Fully biodegradable products with no microplastics or petrochemicals.
  3. Crop health products that safely degrade into organic carbon, nitrogen and phosphate that is restorative for plants and soil.

“AgroSpheres represents a new perspective that answers the call for sustainability in the way we farm and the way we build companies,” said Ameer Shakeel, Co-Founder and CTO of AgroSpheres. “We are deeply inspired by the work we are doing, the culture we are building and our partnering with Zebra around a shared, impact-driven vision. Building our manufacturing facilities, launching our products and forging strategic alliances are on the horizon.”

Lionel Artusio-Payot, Managing Partner of Zebra Impact Ventures, expressed enthusiasm about AgroSpheres’ potential to revolutionize the crop protection industry. “After spending time with the AGS team at their US base and completing our due diligence process, the founders’ talents and drive were clear to us. We believe their breakthrough technology provides the missing link in delivering reliable field performance and opening up new markets for high-performance biopesticides. We see it as one of the most important innovations in crop protection products in the last four decades.”

“We believe AGS represents a true game-changer for the entire biological industry, thanks to both its potential environmental impact and its strong potential to break new ground in terms of exit/valuation in the coming years, with multiple exit opportunities such as private equity deals, IPO and M&A,” said Pierre Jouve, Investment Manager of Zebra Impact Ventures. “We look forward to supporting AGS with impact and regulatory guidance as well as developing its presence in the EU market.”

With this significant Series B investment, AgroSpheres is well-positioned to push for growth as it launches products and expands partnerships with major industry players.

Read more here.

Recent News

05/13/2026

BRAINBox Solutions Announces Appointment of Richard H. Noel as Chief Product and Commercial Officer

BRAINBox Solutions today announced the appointment of Richard H. Noel to the newly created position of Chief Product and Commercial Officer. Richard brings more than 10 years of experience in molecular and point-of-care diagnostics, at Roche Diagnostics, LumiraDx, and bioMérieux. “Richard, whose expertise spans market analytics, global product management, and senior commercial leadership, has established

05/12/2026

Phlow Corp. Appoints Tim Mayleben Chief Executive Officer as Co-Founder Dr. Eric Edwards Transitions to Chairman Emeritus and Strategic Advisor

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Tim Mayleben has been appointed Chief Executive Officer, effective immediately. Eric Edwards, M.D., Ph.D., Phlow’s co-founder and former CEO, has transitioned to the role of Chairman Emeritus and Strategic Advisor to the CEO and Board of Directors. The leadership

05/09/2026

NIRSense Supports the US Army in the Indo-Pacific with Tissue Oxygenation Assessment for Battlefield Casualty Care at Balikatan-26

NIRSense, Inc. today announced its participation in Balikatan-26, supporting the US Army Pacific (USARPAC)’s 18th Theater Medical Command (18th TMC) as they evaluate advanced approaches to battlefield casualty assessment using portable tissue oxygen saturation (StO₂) monitoring. Balikatan, meaning “shoulder-to-shoulder,” is the longstanding U.S.-Philippine bilateral exercise designed to strengthen interoperability and regional readiness through combined operations